We claim:

1. Semisolid pharmaceutical preparation for transdermal use, which contains particles of at least one active ingredient coated with a volatile silicone oil or a mixture of such oils dispersed in an aqueous gel or cream base vehicle with the proviso that the active ingredient is different from clotrimazole, metronidazole or cetirizine.
2. Pharmaceutical preparation according to claim 1, characterized in that the volatile silicone oil component is selected from hexamethyldisiloxane, octamethyltrisiloxane, decamethyl pentacyclosiloxane or mixtures thereof.
3. Pharmaceutical preparation according to clam 1 or claim 2, characterized in that the active ingredient(s) are selected from pharmaceutically active compounds suitable for the treatment or prevention of infectious diseases, cancerous or haematological diseases, endocrinological, metabolic or nutritional diseases, diseases of the central nervous system, psychiatric, behaviourial and obsessive (behavioural) disorders, compulsive disorder, sexual and sexually transmitted disease, disorders or conditions related to the mental or cognitive function, neurological disorders, stroke, ophtalmological diseases, dental diseases, otolaryngological diseases, cardiovascular or cerebrovascular diseases, pulmonological diseases, gastroenterological or hepatological diseases, diseases of the bone-arthritic and the muscular system, immunological diseases, obstertic or gynaecological or andrological diseases or effective for the treatment of injuries caused by external physical effects or against external or internal parasites, insects or microbes or useful as a diagnostic or disinfectant ingredient.

4. Pharmaceutical preparation according to any of claims 1 to 3, wherein the vehicle is a hydrophilic gel base containing one or more gel-forming polymer, water and optionally other auxiliary agents.

5. Pharmaceutical preparation according to any of claims 1 to 4, characterized in that the gel-forming polymer in the vehicle is a carboxyvinyl polymer, hydroxypropylmethylcellulose or a mixture thereof.

6. Semisolid pharmaceutical preparation for transdermal use, containing 0.05-5.00 weight% pharmaceutically active ingredient coated with 0.5-10.0 weight% volatile silicone oil selected from hexamethylsiloxane, octamethyltrisiloxane, decamethylcyclo-pentasiloxane or a mixture thereof dispersed in an aqueous gel base containing 0.5-5.0 weight% hydrophylic polymer, preferably a carboxyvinyl polymer, hydroxypropyl-methylcellulose or a mixture thereof.

7. Pharmaceutical preparation according to claim 3, characterized in that the active ingredient is different from acyclovir, piroxicam, meloxicam, ibuprofen, diclofenac sodium and potassium salt, clotrimazole, bifonazole, metronidazole, nifedipine, nitroglycerol and cetirizine.

8. Pharmaceutical preparation according to any of claims 1 to 6 comprising lidocaine base, phenobarbital, econazole base, sulfadimidine, albumin tannate, papaverine, drotaverine, benzydamine, atropine base, micronized sulfur, pentosane polysulfate, troxerutine, pancreatine, neomycine base, hydrocortison, sulfamethoxazole, trimetoprim, amidazophene, novamidazofen, paracetamol, alprazolam, theophyilline or caffeine.

9. Pharmaceutical preparation according to any of claims 1 to 8 prepacked in a container suitable for metered delivery.
10. Pharmaceutical preparation according to any of claims 1 to 9 suitable for producing topical therapeutical effect.
11. Pharmaceutical preparation according to any of claims 1 to 9 suitable for producing local therapeutical effect.
12. Pharmaceutical preparation according to any of claims 1 to 9 suitable for producing systemic therapeutical effect.
13. Method for the preparation of the pharmaceutical formulation according to any of claims 1 to 7, which comprises mixing the active ingredient optionally in micronized form with a volatile silicone oil or a mixture of such oils and dispersing the thus pbtained suspension in an aqueous gel, ointment or cream base in such a manner that the silicone coating forms a continous phase around the solid particles in the gel vehicle.

We claim:

1. Semisolid pharmaceutical formulation, which comprises solid active ingredient particles coated with a mixture of 100 cSt or 200 cSt viscosity silicone oil and one or more volatile silicone selected from hexamethyldisiloxane, octamethyltrisiloxane, decamethylcyclopentasiloxane, characterized by that the active ingredient is lidocaine, phenobarbital, nifedipine, econazole, acyclovir, sulfadimidine, albumine tannate, papaverine or meloxicam.
2. Formulation according to claim 1, wherein the ratio of the volatile siloxane component and the active ingredient is between 5 and 12.
3. Formulation according to claim 1, wherein the ratio of the volatile siloxane component and the active ingredient is 12.
4. Formulation according to claim 1 or claim 2, wherein the ratio of the 100 cSt or 200 cSt silicone oil and the active ingredient is between 4 and 6.
5. Formulation according to claim 1 or claim 2, wherein the ratio of the 100 cSt or 200 cSt silicone oil and the active ingredient is between 6.
6. Formulation according to any of claims 1 to 3 containing 0.25-0.50 weight% active ingredient.
7. Formulation according to any of claims 1 to 4, characterized by that said formulation contains 0.5-5.0 weight% hydrophilic polymeric gel forming component, preferably carboxyvinyl copolymer or hydroxymethylcellulose or a mixture thereof.
8. Formulation according to any of claims 1 to 5 packaged suitably for dispensing constant unit doses.